Vaccines / Vaccinations for the Elderly

Immunosenescence — thymic hypoplasia with reduced T-cell production and function, reduced mucosal barrier function, and preserved B-cell numbers — means adaptive immunity is greatly affected while innate immunity is little affected. This increases both infection and malignancy in the elderly.

Inflammageing compounds this with an excessive proinflammatory state, and vaccine responses are correspondingly weaker in older than in younger adults, which is why higher-antigen, adjuvanted and conjugate formulations have been developed for this age group.

Vaccination is the single most cost-effective preventive intervention in geriatric medicine, and belongs in every comprehensive geriatric assessment. Pathy's assessment schedule asks directly: "Have you been vaccinated for flu, pneumonia and tetanus?"

Annually, for patients in all categories — robust, frail, demented and end-of-life. More than 90% of deaths attributed to pneumonia and influenza during epidemics occur in people aged 65 and over.

It reduces hospitalisation rates, is cost-effective, and reduces influenza-associated mortality. In the nursing home it is only about 40% effective at preventing clinical illness but more effective at preventing pneumonia, hospitalisation and death; vaccinating more than 80% of residents prevents outbreaks.

Pathy's also records reductions of about 50% in influenza risk and 70% in influenza mortality, and recommends adjuvanted vaccine for the institutionalised and chronically ill, plus annual vaccination of healthcare personnel, family and regular visitors.

Although less effective at producing protective antibody in older than younger adults, it still reduces pneumococcal bacteraemia in high-risk patients. Textbook position: one dose of PCV13 followed by PPSV23 one year later after age 65; if PPSV23 was given first, only PCV13 is needed; no recommendations exist on re-immunisation.

Supporting trial evidence quoted in Pathy's: the CAPiTA randomised trial in community-dwelling adults over 65 found PCV13 reduced pneumococcal pneumonia by 45%, and a large Japanese nursing-home randomised trial found PPSV23 markedly reduced pneumonia incidence and mortality.

Zoster occurs in up to half of individuals aged 85 or older and PHN affects more than 40% of those over 60. Zostavax (2006) is only 30% protective; Shingrix (2016) is 90% protective.

ACIP recommends a two-dose Shingrix series for all adults aged 50 and above, regardless of prior chickenpox, and including those who previously received Zostavax.

Over half of all tetanus cases occur in people aged 60 or older. All adults should complete a primary series of Td — 0.5 ml intramuscularly, repeated at 2 and 6 months — if the history is incomplete or uncertain.

Booster every 10 years, with at least one booster given as Tdap to cover pertussis, because pertussis immunity wanes. In tetanus-prone wounds, boost every 5 years.

SARS-CoV-2 vaccination according to current guidelines. Pathy's records that safe and effective vaccines available since January 2021 reduce severe disease and mortality, and are indicated for adults over 65, healthcare professionals and family contacts.

Hepatitis C: not a vaccine, but the CDC recommends one-time anti-HCV antibody testing for all adults born 1945–1965 — up to 85% are asymptomatic and at least 50% have normal liver function tests.

Hepatitis B for those with diabetes, chronic kidney or liver disease, or on haemodialysis; travel vaccines as indicated by destination.

All residents and staff with close resident contact should be vaccinated annually against influenza. Zoster vaccination once for selected residents; pneumococcal vaccine once; tetanus booster every 10 years, or every 5 years with tetanus-prone wounds.

Outbreak control: at the onset of a suspected respiratory viral outbreak, obtain nasopharyngeal wash or swab for virus isolation and rapid influenza testing. During a confirmed influenza outbreak, give oseltamivir or zanamivir within 24–48 hours to residents and staff throughout the outbreak, vaccinate unvaccinated residents and staff, restrict visits and movement, suspend group activities, reinforce hand hygiene and mask symptomatic individuals.

Frailty-tailored approach: Pathy's stratifies preventive care into robust, frail, moderately demented and end-of-life categories. Influenza vaccine is given yearly in all four; pneumococcal vaccine once, or considered once at end of life; tetanus primary series is not pursued at end of life.

Contraindications and cautions: live vaccines (Zostavax, MMR, yellow fever) are contraindicated in significant immunosuppression; acute febrile illness defers vaccination; anaphylaxis to a previous dose or component is an absolute contraindication. Age itself is never a contraindication.

The four-vaccine minimum for every Indian patient above 60: annual influenza, pneumococcal conjugate, herpes zoster (two doses), and Td/Tdap every 10 years. Add RSV where available and affordable, and COVID-19 per current guidance.

Conjugate before polysaccharide, always. Giving PCV first produces a better antibody response to shared serotypes. If PPSV23 was inadvertently given first, give a PCV at least 1 year later.

Co-administration is safe. Influenza, pneumococcal, RSV and zoster vaccines may be given at the same visit at separate sites — use every clinical contact, because a missed opportunity in a frail older adult is rarely recovered.

The healthcare-worker argument. Vaccinating staff in long-term care reduces respiratory infection and overall mortality among residents even where resident coverage is already high — a strong point to raise in a policy-flavoured question.

Vaccine efficacy versus effectiveness. Efficacy falls with age, but absolute benefit rises because baseline risk is so much higher. Never use "the vaccine works less well in the elderly" as an argument against vaccinating them.

Live vaccines are the ones to be careful with. Zostavax, MMR and yellow fever are contraindicated in significant immunosuppression. Shingrix, being non-live, is safe and is the reason immunocompromised adults can now be protected against zoster.

Frailty stratification matters. In the end-of-life category, influenza vaccine is still given yearly for symptom burden, pneumococcal vaccine may be considered, but the tetanus primary series is not initiated. Frame this as goal-concordant care.

The Indian policy gap is a ready-made discussion point. India has a world-class paediatric Universal Immunisation Programme but no national adult immunisation schedule; NPHCE does not fund adult vaccines; coverage is under 3%. Recommending integration of adult immunisation into NPHCE is a high-scoring closing sentence.

"Immunosenescence affects adaptive immunity far more than innate immunity, which is why conjugate, adjuvanted and high-dose formulations were developed for older adults."

"More than 90% of pneumonia and influenza deaths during epidemics occur in those aged 65 and over."

"Vaccinating more than 80% of nursing home residents prevents influenza outbreaks."

"ACIP lowered the age for routine pneumococcal conjugate vaccination from 65 to 50 in October 2024, and a single dose of PCV20 or PCV21 now suffices without PPSV23."

"RSV vaccination is a new category — a single, non-annual dose for all adults aged 75 and above."

Close with: "In India the principal barrier is not evidence but implementation — adult vaccination coverage is under 3%, and integrating adult immunisation into NPHCE would be the single highest-yield policy intervention."

Draw a two-column table: Vaccine | Schedule in the elderly. It is the fastest way to earn structural marks.